| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
Program in Immunobiology and Cancer [S. M., D. E. B., E. R. J.], Oklahoma Medical Research Foundation; InterGenetics, Inc. [S. M., E. R. J.]; and Departments of Surgery [M. R. L., D. J. B., E. R. J.] and Pathology [E. R. J.], University of Oklahoma Health Sciences Center, and Veterans Affairs Medical Center [M. R. L., D. J. B.], Oklahoma City, Oklahoma 73104
Prohibitin is a candidate tumor suppressor gene located on human chromosome 17q21, a region of frequent loss of heterozygosity in breast cancers. We showed previously that microinjection of RNA encoded by the prohibitin gene 3'untranslated region (3'UTR) blocks the G1-S transition causing cell cycle arrest in several human cancer cell lines, including MCF7. Two allelic forms (C versus T) of the prohibitin 3'UTR exist, and carriers of the less common variant (Tallele) with a family history of breast cancer exhibited an increased risk of breast cancer. In the present study, we examined the tumor suppressor activity of the prohibitin 3'UTR in human breast cancer cells. Stable clones of MCF7 cells expressing either the C allele or the T allele RNA under the control of the cytomegalovirus promoter were isolated and compared with empty vector clones. Clones expressing the C allele RNA (UTR/C) exhibited significant suppression of growth in cell proliferation assays, inhibition of colony formation in soft agar assays, and suppression of xenograft tumor growth when implanted on nude mice, compared with either T allele expressing or empty vector clones. Immunohistochemical analyses with Ki67 staining confirmed a significant reduction in proliferation of UTR/C tumors. Thus, the C allele of prohibitin 3'UTR produces a functional RNA, whereas a single nucleotide polymorphism creates a null allele (T allele) of which the RNA product has lost activity. Our data demonstrate for the first time that an RNA molecule functions as a tumor suppressor in human breast cancer.
This article has been cited by other articles:
![]() |
J. A. Ross, Z. S. Nagy, and R. A. Kirken The PHB1/2 Phosphocomplex Is Required for Mitochondrial Homeostasis and Survival of Human T Cells J. Biol. Chem., February 22, 2008; 283(8): 4699 - 4713. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. Theiss, T. S. Obertone, D. Merlin, and S. V. Sitaraman Interleukin-6 Transcriptionally Regulates Prohibitin Expression in Intestinal Epithelial Cells J. Biol. Chem., April 27, 2007; 282(17): 12804 - 12812. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. Theiss, R. D. Idell, S. Srinivasan, J.-M. Klapproth, D. P. Jones, D. Merlin, and S. V. Sitaraman Prohibitin protects against oxidative stress in intestinal epithelial cells FASEB J, January 1, 2007; 21(1): 197 - 206. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Lou, N. Fatima, Z. Xiao, S. Stauffer, G. Smythers, P. Greenwald, and I. U. Ali Proteomic profiling identifies cyclooxygenase-2-independent global proteomic changes by celecoxib in colorectal cancer cells. Cancer Epidemiol. Biomarkers Prev., September 1, 2006; 15(9): 1598 - 1606. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Zhu, K. Fukada, H. Zhu, and N. Kyprianou Prohibitin and Cofilin Are Intracellular Effectors of Transforming Growth Factor {beta} Signaling in Human Prostate Cancer Cells. Cancer Res., September 1, 2006; 66(17): 8640 - 8647. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Rastogi, B. Joshi, G. Fusaro, and S. Chellappan Camptothecin Induces Nuclear Export of Prohibitin Preferentially in Transformed Cells through a CRM-1-dependent Mechanism J. Biol. Chem., February 3, 2006; 281(5): 2951 - 2959. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Fu, N. Luo, R. L. Klein, and W. T. Garvey Adiponectin promotes adipocyte differentiation, insulin sensitivity, and lipid accumulation J. Lipid Res., July 1, 2005; 46(7): 1369 - 1379. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Jenkins, M. Bitner-Glindzicz, S. Malcolm, C.-C. A. Hu, J. Allison, P. J.D. Winyard, A. M. Gullett, D. F.M. Thomas, R. A. Belk, S. A. Feather, et al. De Novo Uroplakin IIIa Heterozygous Mutations Cause Human Renal Adysplasia Leading to Severe Kidney Failure J. Am. Soc. Nephrol., July 1, 2005; 16(7): 2141 - 2149. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. De Celle, F. Vanrobaeys, P. Lijnen, W. M. Blankesteijn, S. Heeneman, J. Van Beeumen, B. Devreese, J. F. M Smits, and B. J. A Janssen Alterations in mouse cardiac proteome after in vivo myocardial infarction: permanent ischaemia versus ischaemia-reperfusion Exp Physiol, July 1, 2005; 90(4): 593 - 606. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. M. Harrison, D. Zheng, Z. Zhang, N. Carriero, and M. Gerstein Transcribed processed pseudogenes in the human genome: an intermediate form of expressed retrosequence lacking protein-coding ability Nucleic Acids Res., April 28, 2005; 33(8): 2374 - 2383. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |